Shanghai MicuRx Pharmaceutical Co. Ltd. A

China Jushi announced that it expects net profit attributable to shareholders of the listed company for the first three quarters of 2026 to be between 5.136 billion yuan and 5.393 billion yuan, up 100% to 110% year on year. The change is mainly due to increased demand in major downstream application areas for fiberglass and a simultaneous rise in product volume and prices. On the same day, several other companies released earnings forecasts. Kinwong Electronic expects third-quarter net profit of 912 million yuan to 1.089 billion yuan, up 205.46% to 264.74% year on year, benefiting from faster mass production and shipments of high-performance PCBs in high-speed communications and AI data infrastructure. Delton Technology expects net profit of 1.45 billion yuan to 1.5 billion yuan for the first three quarters, up 100.33% to 107.23%, focusing on the computing power PCB market. Hongfuhan expects net profit of 170 million yuan to 200 million yuan for the first three quarters, up 108.19% to 144.93%, with mass production and delivery of liquid cooling plate cabinet module business becoming the core incremental driver. Bohai Leasing's controlling subsidiary Avolon, through its wholly owned subsidiary AALL, signed an agreement with Boeing to purchase 140 B737 MAX series aircraft. Based on Boeing's published list prices, the total value does not exceed 26.953 billion US dollars, while the actual purchase price carries a certain discount. The deal still needs shareholder approval and is expected to be fully delivered by the end of 2036. MicuRx Pharmaceuticals plans to sign an exclusive license agreement for the MRX-23 project and a platform technology cooperation agreement with ClearideBio of Switzerland. The upfront payment is 1 million US dollars, the nominal cap for MRX-23 development, registration and sales milestone payments totals 223 million US dollars, and the total payment cap when all platform cooperation project options are exercised and all milestones are achieved is 750 million US dollars. China Northern Rare Earth and Baogang Group both announced that the rare earth concentrate transaction price for the fourth quarter of 2026 will be adjusted to 38,769 yuan per ton excluding tax, up 0.53% quarter on quarter. Wuliangye has cumulatively repurchased 16.1278 million shares, with a total amount paid of about 1.201 billion yuan. ST Nachuan has been placed on file for investigation by the China Securities Regulatory Commission for suspected illegal information disclosure in its 2023 annual report. Yu Faxiang, the actual controller of Xiangyuan Cultural Tourism and Jiaojian Co., Ltd., has also been placed on file for investigation by the CSRC for suspected illegal information disclosure.

MicuRx Pharmaceuticals announced that it plans to sign an exclusive license agreement for the MRX-23 program and a platform technology collaboration agreement with ClearideBio of Switzerland. The former involves a worldwide exclusive license for the MRX-23 program; the latter is a multi-program option collaboration based on the company's independently developed STOPIN antibody-drug conjugate platform with a novel camptothecin payload, under which ClearideBio may exercise options for an agreed number of targets or target combinations in accordance with the agreement. Under the MRX-23 license agreement, an upfront payment of 1 million US dollars will be paid as agreed after the agreement takes effect, and this payment is non-refundable once made. Near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. The nominal cap on research, registration, and sales milestone payments for MRX-23 totals 223 million US dollars; when all options under the platform collaboration are exercised and all milestones are achieved, the total payment cap is 750 million US dollars.